pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

Blueprint Medicines Corp

updated 12d ago
Website ↗
community read0 votes
pipeline
4
marketed
2
phase 3
1
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(4)

pipeline depth4 products
Phase 2: 1Phase 3: 1Marketed: 2
1Phase 21Phase 32Marketed
Marketed
avapritinib
Gastrointestinal Stromal Tumor (GIST)
Marketed
pralsetinib
Solid Tumor
Phase 3
elenestinib
Systemic Mastocytosis
Phase 2
BLU-808
Chronic Inducible Urticaria

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase2A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutationsrecruitingn=265
  • phase3(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosisrecruitingn=534
  • —An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM)recruitingn=150
  • phase2Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)active not recruitingn=105
  • phase2(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosiscompletedn=107
  • —A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germanyrecruitingn=80
  • —Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populationsrecruitingn=450
  • phase1A Study of Elenestinib in Healthy Adult Female Participantscompletedn=20
more trials →
🐶 Hiring Signal
No open roles indexed yet — view Blueprint Medicines Corp jobs →

News

no news has mentioned this company yet
identifiers
source
globaldata
top tags
Oncology3Dermatology1NSCLC1
mentioned in
0news items
entity-linker matched

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?